Zelandopam

Zelandopam
Clinical data
Other names	Selandopam; (–)-(S)-7,8-Dihydroxy-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline; 7,8-DDPTI; YM-435; YM435; MYD-37; MYD37
Routes of; administration	Intravenous administration
Drug class	Dopamine D1-like receptor agonists
Identifiers
	IUPAC name (4S)-4-(3,4-dihydroxyphenyl)-1,2,3,4-tetrahydroisoquinoline-7,8-diol;
CAS Number	139233-53-7 ; 138086-00-7 (hydrochloride);
PubChem CID	3078105;
ChemSpider	2336394;
UNII	IR6XYD8SAX;
ChEMBL	ChEMBL2105532;
CompTox Dashboard (EPA)	DTXSID2048820 ;
Chemical and physical data
Formula	C15H15NO4
Molar mass	273.288 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C1[C@H](C2=C(CN1)C(=C(C=C2)O)O)C3=CC(=C(C=C3)O)O;
	InChI InChI=1S/C15H15NO4/c17-12-3-1-8(5-14(12)19)10-6-16-7-11-9(10)2-4-13(18)15(11)20/h1-5,10,16-20H,6-7H2/t10-/m0/s1; Key:FULLEMQICAKPOE-JTQLQIEISA-N;

Zelandopam (INNTooltip International Nonproprietary Name; developmental code names YM-435, MYD-37) is a selective dopamine D₁-like receptor agonist related to fenoldopam which was under development in Japan for the treatment of hypertension and heart failure but was never marketed.^[1]^[2]^[3] The drug was being developed for use by intravenous administration.^[1] The development of zelandopam appears to have been discontinued by the early 2000s.^[1] It was first described in the scientific literature by 1991.^[4]

References

^ ^a ^b ^c "Zelandopam hydrochloride". AdisInsight. 22 May 2002. Retrieved 21 October 2024.
^ Doggrell SA (May 2002). "The therapeutic potential of dopamine modulators on the cardiovascular and renal systems". Expert Opin Investig Drugs. 11 (5): 631–644. doi:10.1517/13543784.11.5.631. PMID 11996645.
^ Vaz de Castro PA, Jose PA, Simões e Silva AC (August 2022). "Interactions between the intrarenal dopaminergic and the renin-angiotensin systems in the control of systemic arterial pressure". Clin Sci (Lond). 136 (16): 1205–1227. doi:10.1042/CS20220338. PMID 35979889.
^ Giammattei, C. E., Handa, R. K., & Strandhoy, J. W. (1991). The DA1 agonists, YM435 (YM) and fenoldopam (F), inhibit oxygen consumption (QO2) in rat renal proximal tubules. Pharmacologist, 33, 210p. https://scholar.google.com/scholar?cluster=13521937496129958590

This antihypertensive-related article is a stub. You can help Wikipedia by expanding it.